NIH-funded study shows early intervention has best outcomes

Team-based treatment is better for first episode psychosis

 

Bethesda, MD, USA (October 20, 2015) – New research shows that treating people with first episode psychosis with a team-based, coordinated specialty care approach produces better clinical and functional outcomes than typical community care. Investigators also found that treatment is most effective for people who receive care soon after psychotic symptoms begin.


John M. Kane, M.D. heads the RAISE Early Treatment Program, one of two studies that make up the Recovery After an Initial Schizophrenia Episode (RAISE) project funded by the National Institute of Mental Health (NIMH). Kane is professor and chairman, Dept. of Psychiatry at The Hofstra North Shore-LIJ School of Medicine and The Zucker Hillside Hospital. The team’s research is published online today by The American Journal of Psychiatry.

 

Kane and his colleagues trained clinical staff at real-world clinics around the country to use a coordinated specialty care treatment program called NAVIGATE. The program featured a team of specialists who worked with each client to create a personalized treatment plan. The specialists offered recovery-oriented psychotherapy, low doses of antipsychotic medications, family education and support, case management, and work or education support, depending on the individual’s needs and preferences. The treatment was guided by shared decision making between the client and team. In addition, the treatment involved family members as much as possible.

 

"The goal is to link someone experiencing first episode psychosis with a coordinated specialty care team as soon as possible after psychotic symptoms begin," said Kane. "Our study shows that this kind of treatment can be implemented in clinics around the country. It improves outcomes and the effects are greater for those with a shorter duration of untreated psychosis."

 

There were 404 individuals with first episode psychosis enrolled in the study (223 at clinics using the NAVIGATE coordinated specialty care program and 181 at clinics using ‚typical-care‘). Patients treated at clinics using the NAVIGATE program remained in treatment longer, and experienced greater improvement in their symptoms, interpersonal relationships, quality of life, and involvement in work and school compared with patients at the typical-care sites.

 

In addition, the Kane team found that the amount of time between the beginning of psychotic symptoms and the beginning of treatment (called the duration of untreated psychosis or DUP) was very important in determining treatment outcomes. Half of study participants had a DUP under 74 weeks and half had longer periods of untreated psychosis. NAVIGATE patients with a DUP of less than 74 weeks had much greater improvement in quality of life and overall symptoms compared with those with a longer DUP and those in community care.

 

"Clearly, the take-home message here is that outcomes for young people with early psychosis are better when clinicians do the right things at the right time," said Robert Heinssen, Ph.D., director of the Division of Services and Intervention Research at NIMH. "Dr. Kane’s work is having an immediate impact on clinical practice in the U.S. and is setting a new standard of care. We’re seeing more states adopt coordinated specialty care programs for first episode psychosis, offering hope to thousands of clients and family members who deserve the best care that science can deliver."

 

 

 

Reference

 

Kane, J.M., Robinson, D.G., Schooler, et al. Comprehensive Versus Usual Community Care for First Episode Psychosis: Two-Year Outcomes From the NIMH RAISE Early Treatment Program. American Journal of Psychiatry (in press)

 

The Recovery After an Initial Schizophrenia Episode (RAISE) project is a large-scale research initiative that began, in 2008. RAISE is comprised of two studies examining different aspects of coordinated specialty care treatments for people experiencing first episode psychosis. For more information, visit http://www.nimh.nih.gov/RAISE. For more information about NAVIGATE, visit https://raiseetp.org)

 

About the National Institute of Mental Health (NIMH): The mission of the NIMH is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery and cure. For more information, visit http://www.nimh.nih.gov

 

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov

 

 


NIH/National Institute of Mental Health, 20.10.2015 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…